Article Data

  • Views 546
  • Dowloads 130

Original Research

Open Access

The ovarian cancers in geriatric population: the validity of inflammatory markers, malignancy risk indices 1, 2, 3, 4, and CA-125 levels in malignancy discrimination of adnexal masses

  • F. Vural1,*,
  • N. Aka1
  • S. Ertaş1
  • G. Köse1
  • E.C. Tüfekçi1

1Haydarpaşa Numune Training and Research Hospital, Gynecology and Obstetrics Clinic, Istanbul, Turkey

DOI: 10.12892/ejgo3271.2016 Vol.37,Issue 6,December 2016 pp.846-851

Published: 10 December 2016

*Corresponding Author(s): F. Vural E-mail: fisunvural@yahoo.com.tr

Abstract

Purpose: To investigate the predictive value of the Risk of Malignancy Index (RMI), CA-125, and inflammatory markers in discriminating ovarian cancers (OCs). Materials and Methods: The postmenopausal (PM) women (n = 139) with adnexal masses who underwent surgery were included. The predictive value of CA-125, RMI (1, 2, 3, and 4) and inflammatory markers [neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR)] were calculated in geriatric (G) and non-geriatric women. Results: OCs had significantly increased NLR and PLR. RMI models were highly reliable in PM (Kappa: 0.642-0.715; AUC: 0.907-0.934). CA-125 measurement alone had good accuracy and moderate reliability in PM (kappa: 0.507-0.587), excellent accuracy and moderate reliability in G, NLR, and PLR predicting OCs, showed fair agreement in the PM, while PLR had a moderate agreement with G. Conclusion: RMI algorithms were the best models for malignancy prediction. However, the rise of PLR and CA-125 levels in a G population may be used as referring adnexal masses to gynecologic oncologists.


Keywords

Ovarian cancers; Risk of malignancy risk index; Adnexal masses; CA-125; cancer screening; Neutrophil lymphocyte ratio; Platelet lymphocyte ratio; Geriatric; Menopause.


Cite and Share

F. Vural,N. Aka,S. Ertaş,G. Köse,E.C. Tüfekçi. The ovarian cancers in geriatric population: the validity of inflammatory markers, malignancy risk indices 1, 2, 3, 4, and CA-125 levels in malignancy discrimination of adnexal masses. European Journal of Gynaecological Oncology. 2016. 37(6);846-851.

References

[1] United Nations, Department of Economic and Social Affairs, Population

Division.: “World Population Ageing 2013”. ST/ESA/

SER.A/348. New York: United Nations Publication, 2013.

[2] Trillsch F., Woelber L., Eulenburg C., Braicu I., Lambrechts

S., Chekerov R., et al.: “Treatment reality in elderly patients with advanced

ovarian cancer: a prospective analysis of the OVCADconsortium”.

J. Ovarian Res., 2013, 6, 42.

[3] Su Z, Graybill WS, Zhu Y.: “Detection and monitoring of ovarian

cancer”. Clin. Chim. Acta, 2013, 415, 341.

[4] Jacobs I., Bast R.C. Jr.: “ The CA-125 tumor-associated antigen: a review

of the literature”. Hum. Reprod., 1989, 4, 1.

[5] Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas

J.G.: “A risk of malignancy incorporating CA-125, ultrasound and

menopausal status fort he accurate preoperative diagnosis of ovarian

cancer”. Br. J. Obstet. Gynecol., 1990, 97, 922.

[6] Tingulstad S., Hagen B., Skjeldestad F.E., Onsrud M., Kiserud T.,

Halvorsen T., et al.: “Evaluation of risk of malignancy index based

on serum CA-125, ultrasound findings and menopausal status in the

preoperative diagnosis of pelvic masses”. Br. J. Obstet. Gynecol.,

1996, 102, 826.

[7] Tingulstad S., Hagen B., Skjeldestad F.E., Halvorsen T., Nustad K.,

Onsrud M.: “The risk of malignancy index to evaluate potential ovarian

cancers in local hospitals”. Obstet. Gynecol., 1999, 93, 448.

[8] Yamamoto Y., Yamada R., Oguri H., Maeda N., Fukaya T.: “ Comparison

of four malignancy risk indices in the preoperative evaluation

of patients with pelvic masses”. Eur. J. Obstet. Gynecol. Reprod.

Biol., 2009, 144, 163.

[9] Terzic M., Dotlic J., Likic I., Brndusic N., Pilic I., Ladjevic N., et

al.: “Risk of malignancy index validity assessment in premenopausal

and postmenopausal women with adnexal tumors”. Taiwan J. Obstet.

Gynecol., 2013, 52, 253.

[10] Sayasneh A., Wynants L., Preisler J., Kaijser J., Jonhsın S., Stalder C.,

et al.: “Multicentre external validation of IOTA prediction models and

RMI by operators with varied training”. Br. J. Cancer, 2013, 108, 2448.

[11] Kaijser J., Sayasneh A., Van Hoorde K.,Ghaem-Maghami S., Bourne

T., Timmerman D., Van Calster B.: “Presurgical diagnosis of adnexal

tumors using mathematical models and scoring systems: a systematic

review and meta-analysis”. Hum. Reprod. Update, 2014, 20, 449.

[12] Geomini P., Kruitwagen R., Bremer G.L., Cnossen J., Mol B.W.:

“The accuracy of risk scores in predicting ovarian malignancy: a systematic

review”. Obstet. Gynecol., 2009, 113, 384.

[13] Donskov F.: “Immunomonitoring and prognostic relevance of neutrophils

in clinical trials”. Semin. Cancer Biol., 2013, 23, 200.

[14] Balkwill F., Mantovani A.: “Inflammation and cancer: back to Virchow?

” Lancet, 2001, 357, 539.

[15] Coussens L.M., Werb Z.: “Inflammation and cancer”. Nature, 2002,

420, 860.

[16] Salazar-Onfray F., Lopez M.N., Mendoza-Naranjo A.: “Paradoxical

effects of cytokines in tumor immune surveillance and tumor escape”.

Cytokine Growth Factor Rev., 2007, 18, 171–182.

[17] Stone R.L., Nick A.M., McNeish I.A., Balkwill F., Han H.D., Bottsford-

Miller J., et al.: “Paraneoplastic thrombocytosis in ovarian cancer”.

N. Engl. J. Med., 2012, 366, 610.

[18] Krenn-Pilko S., Langsenlehner U., Thurner E.M., Stojakovic

T., Pichler M., Gerger A., et al.: “The elevated preoperative plateletto-

lymphocyte ratio predicts poor prognosis in breast cancer patients”.

Br. J. Cancer, 2014, 110, 2524.

[19] Templeton A.J., McNamara M.G., Šeruga B., Vera-Badillo F.E.,

Aneja P., Ocaña A., et al.: “Prognostic role of neutrophil-tolymphocyte

ratio in solid tumors: a systematic review and metaanalysis”.

J. Natl. Cancer Inst., 2014, 106, dju124.

[20] Templeton A.J., Ace O., McNamara M.G., Al-Mubarak M., Vera-

Badillo F.E., Hermanns T., et al.: “Prognostic role of platelet to

lymphocyte ratio in solid tumors: a systematic review and metaanalysis”.

Cancer Epidemiol. Biomarkers Prev., 2014, 23, 1204.

[21] Cho H., Hur H.W., Kim S.W., Kim S.H., Kim J.H., Kim Y.T., Lee K.:

“Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial

ovarian cancer and predicts survival after treatment”. Cancer Immunol

Immunother., 2009, 58, 15.

[22] Thavaramara T., Phaloprakarn C., Tangjitgamol S., Manusirivithaya

S.: “Role of neutrophil to lymphocyte ratio as a prognostic indicator

for epithelial ovarian cancer”. J. Med. Assoc. Thai, 2011, 94, 871.

[23] Yildirim M., Demir Cendek B., Filiz Avsar A.: “Differentiation between

benign and malignant ovarian masses in the preoperative period

using neutrophil-to-lymphocyte and platelet-tolymphocyte

ratios”. Mol. Clin. Oncol., 2015, 3, 317.

[24] Asher V., Lee J., Innamaa A., Bali A.: “Preoperative platelet lymphocyte

ratio as an independent prognostic marker in ovarian cancer”.

Clin. Transl. Oncol., 2011, 13, 499.

[25] Raungkaewmanee S., Tangjitgamol S., Manusirivithaya S., Srijaipracharoen

S., Thavaramara T.: “Platelet to lymphocyte ratio as a

prognostic factor for epithelial ovarian cancer”. J. Gynecol.

Oncol., 2012, 23, 265.

[26] Kokcu A., Kurtoglu E., Celik H., Tosun M., Malatyalıoglu E.,

Ozdemir A.Z.: “ May the platelet to lymphocyte ratio be a prognostic

factor for epithelial ovarian cancer?” Asian Pac. J. Cancer Prev.,

2014, 15, 9781.

[27] American College of Obstetricians and Gynecologists.: “ACOG

Committee Opinion: number 280, December 2002. The role of the

generalist obstetrician-gynecologist in the early detection of ovarian

cancer”. Obstet. Gynecol., 2002, 100, 14, 13.

[28] Rufford B.D., Jacobs I.J. : “Green-top Guideline No. 34. Ovarian cysts

in postmenopausal women”. London, UK: Royal College of Obstetricians and Gynaecologists, 2003. Available at: http:// www.rcog.org.uk/files/rcog-corp/GTG3411022011.pdf

[29] Suh D.H., Kim H.S., Chung H.H., Kim J.W., Park N.H., Song Y.S., Kang S.B.: “Preoperative systemic inflammatory response markers in predicting lymph node metastasis in endometrioid endometrial adenocarcinoma”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2012, 162, 206.

[30] Lee Y.Y., Choi C.H., Kim H.J., Kim T.J., Lee J.W., Lee J.H., et al.: “Pretreatment neutrophil: lymphocyte ratio as a prognostic factor in cervical carcinoma”. Anticancer Res., 2012, 32, 1555.

[31] Kwon H.C., Kim S.H., Oh S.Y., Lee S., Lee J.H., Choi H.J., et al.: “Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer”. Biomarkers, 2012, 17, 216.

[32] Smith R.A., Ghaneh P., Sutton R., Raraty M., Campbell F., Neoptolemos J.P.: “Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio”. J. Gastrointest. Surg., 2008, 12, 1422.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top